These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 9443622

  • 1. Pharmacokinetics of CPT-11 in rhesus monkeys.
    Inaba M, Ohnishi Y, Ishii H, Tanioka Y, Yoshida Y, Sudoh K, Hakusui H, Mizuno N, Ito K, Sugiyama Y.
    Cancer Chemother Pharmacol; 1998; 41(2):103-8. PubMed ID: 9443622
    [Abstract] [Full Text] [Related]

  • 2. Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPT-11.
    Sasaki Y, Yoshida Y, Sudoh K, Hakusui H, Fujii H, Ohtsu T, Wakita H, Igarashi T, Itoh K.
    Jpn J Cancer Res; 1995 Jan; 86(1):111-6. PubMed ID: 7737902
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetic characteristics of the novel anticancer agent CPT-11 and its active metabolite in plasma and lung lymph fluid following intravenous administration to sheep.
    Koizumi T, Kubo K, Hanaoka M, Miyahara T, Kaneki T, Yamamoto H, Ge RL, Fujimoto K, Kobayashi T, Sekiguchi M.
    Arzneimittelforschung; 1998 Nov; 48(11):1097-100. PubMed ID: 9850432
    [Abstract] [Full Text] [Related]

  • 4. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials.
    Chabot GG, Abigerges D, Catimel G, Culine S, de Forni M, Extra JM, Mahjoubi M, Hérait P, Armand JP, Bugat R.
    Ann Oncol; 1995 Feb; 6(2):141-51. PubMed ID: 7786822
    [Abstract] [Full Text] [Related]

  • 5. Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis.
    Xie R, Mathijssen RH, Sparreboom A, Verweij J, Karlsson MO.
    J Clin Oncol; 2002 Aug 01; 20(15):3293-301. PubMed ID: 12149304
    [Abstract] [Full Text] [Related]

  • 6. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.
    Rowinsky EK, Grochow LB, Ettinger DS, Sartorius SE, Lubejko BG, Chen TL, Rock MK, Donehower RC.
    Cancer Res; 1994 Jan 15; 54(2):427-36. PubMed ID: 8275479
    [Abstract] [Full Text] [Related]

  • 7. Simultaneous determination of the camptothecin analogue CPT-11 and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in cancer patients.
    Barilero I, Gandia D, Armand JP, Mathieu-Boué A, Ré M, Gouyette A, Chabot GG.
    J Chromatogr; 1992 Mar 27; 575(2):275-80. PubMed ID: 1629304
    [Abstract] [Full Text] [Related]

  • 8. A limited sampling model for estimating pharmacokinetics of CPT-11 and its metabolite SN-38.
    Sasaki Y, Mizuno S, Fujii H, Ohtsu T, Wakita H, Igarashi T, Itoh K, Sekine I, Miyata Y, Saijo N.
    Jpn J Cancer Res; 1995 Jan 27; 86(1):117-23. PubMed ID: 7737903
    [Abstract] [Full Text] [Related]

  • 9. Clinical pharmacokinetics of irinotecan.
    Chabot GG.
    Clin Pharmacokinet; 1997 Oct 27; 33(4):245-59. PubMed ID: 9342501
    [Abstract] [Full Text] [Related]

  • 10. Nonlinear pharmacokinetics of CPT-11 in rats.
    Kaneda N, Yokokura T.
    Cancer Res; 1990 Mar 15; 50(6):1721-5. PubMed ID: 2306726
    [Abstract] [Full Text] [Related]

  • 11. Plasma pharmacokinetics of 7-ethyl-10-hydroxycamptothecin (SN-38) after intravenous administration of SN-38 and irinotecan (CPT-11) to rats.
    Kaneda N, Hosokawa Y, Yokokura T, Awazu S.
    Biol Pharm Bull; 1997 Sep 15; 20(9):992-6. PubMed ID: 9331983
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials.
    Rivory LP, Haaz MC, Canal P, Lokiec F, Armand JP, Robert J.
    Clin Cancer Res; 1997 Aug 15; 3(8):1261-6. PubMed ID: 9815808
    [Abstract] [Full Text] [Related]

  • 13. Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates.
    Blaney SM, Takimoto C, Murry DJ, Kuttesch N, McCully C, Cole DE, Godwin K, Balis FM.
    Cancer Chemother Pharmacol; 1998 Aug 15; 41(6):464-8. PubMed ID: 9554590
    [Abstract] [Full Text] [Related]

  • 14. Limited sampling models for simultaneous estimation of the pharmacokinetics of irinotecan and its active metabolite SN-38.
    Chabot GG.
    Cancer Chemother Pharmacol; 1995 Aug 15; 36(6):463-72. PubMed ID: 7554037
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics of prolonged-release CPT-11-loaded microspheres in rats.
    Machida Y, Onishi H, Kurita A, Hata H, Morikawa A, Machida Y.
    J Control Release; 2000 May 15; 66(2-3):159-75. PubMed ID: 10742577
    [Abstract] [Full Text] [Related]

  • 16. Simple and rapid determination of irinotecan and its metabolite SN-38 in plasma by high-performance liquid-chromatography: application to clinical pharmacokinetic studies.
    Escoriaza J, Aldaz A, Castellanos C, Calvo E, Giráldez J.
    J Chromatogr B Biomed Sci Appl; 2000 Apr 14; 740(2):159-68. PubMed ID: 10821401
    [Abstract] [Full Text] [Related]

  • 17. Involvement of up-regulation of hepatic breast cancer resistance protein in decreased plasma concentration of 7-ethyl-10-hydroxycamptothecin (SN-38) by coadministration of S-1 in rats.
    Yokoo K, Hamada A, Watanabe H, Matsuzaki T, Imai T, Fujimoto H, Masa K, Imai T, Saito H.
    Drug Metab Dispos; 2007 Sep 14; 35(9):1511-7. PubMed ID: 17537871
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetic modulation of irinotecan metabolites by sulphobromophthalein in rats.
    Itoh T, Itagaki S, Sasaki K, Hirano T, Takemoto I, Iseki K.
    J Pharm Pharmacol; 2004 Jun 14; 56(6):809-12. PubMed ID: 15231047
    [Abstract] [Full Text] [Related]

  • 19. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice.
    Bissery MC, Vrignaud P, Lavelle F, Chabot GG.
    Anticancer Drugs; 1996 Jun 14; 7(4):437-60. PubMed ID: 8826613
    [Abstract] [Full Text] [Related]

  • 20. Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients.
    Rivory LP, Chatelut E, Canal P, Mathieu-Boué A, Robert J.
    Cancer Res; 1994 Dec 15; 54(24):6330-3. PubMed ID: 7987823
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.